Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial

Schizophrenia Research

Volumn 160, Issue 1-3, 2014, Pages 73-79

  Ramsey, Timothy L ^a   Brennan, Mark D ^a  

^a NuLease Medical Solutions   (United States)

Author keywords

Olanzapine; Perphenazine; Pharmacogenetics; Quetiapine; Risperidone; Schizophrenia; Ziprasidone

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LEUCINE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERINE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; GLP1R PROTEIN, HUMAN; GLUCAGON RECEPTOR; NEUROLEPTIC AGENT; PHARMACOLOGICAL BIOMARKER; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GLP1R GENE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; BIOLOGICAL MODEL; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; GENOTYPING TECHNIQUE; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIOMARKERS, PHARMACOLOGICAL; DIBENZOTHIAZEPINES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPING TECHNIQUES; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HAPLOTYPES; HUMANS; MALE; MODELS, GENETIC; PERPHENAZINE; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; QUETIAPINE FUMARATE; RECEPTORS, GLUCAGON; REGRESSION ANALYSIS; RISPERIDONE; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84928225418     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.09.038     Document Type: Article

References (39)

1. Adkins D.E., Aberg K., McClay J.L., Bukszar J., Zhao Z., Jia P., Stroup T.S., Perkins D., McEvoy J.P., Lieberman J.A., Sullivan P.F., van den Oord E.J. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol. Psychiatry 2011, 16:321-332.
2. Ascher-Svanum H., Stensland M., Zhao Z., Kinon B.J. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 2005, 5:3.
3. Bai Y.M., Lin C.C., Chen J.Y., Lin C.Y., Su T.P., Chou P. Association of initial antipsychotic response to clozapine and long-term weight gain. Am. J. Psychiatry 2006, 163:1276-1279.
4. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
5. Benjamini Y., Hockberg Y. On the adaptive control of the false discovery rate in multiple testing with independent statistics. J. Educ. Behav. Stat. 2000, 25:60-83.
6. Bhagwagar Z., Hafizi S., Cowen P.J. Increased salivary cortisol after waking in depression. Psychopharmacology (Berl). 2005, 182:54-57.
7. Brandl E.J., Tiwari A.K., Chowdhury N.I., Zai C.C., Lieberman J.A., Meltzer H.Y., Kennedy J.L., Muller D.J. Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. Pharmacogenomics 2014, 15:423-431.
8. Brunetti L., Orlando G., Recinella L., Leone S., Ferrante C., Chiavaroli A., Lazzarin F., Vacca M. Glucagon-like peptide 1 (7-36) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus. Peptides 2008, 29:1377-1381.
9. Chohen J. Statistical Power Analysis for the Behavioral Sciences Lawrence Erlbaum Associates 1988.
10. Das C., Mendez G., Jagasia S., Labbate L.A. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann. Clin. Psychiatry 2012, 24:225-239.
11. Dixit T.S., Sharma A.N., Lucot J.B., Elased K.M. Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis. Physiol. Behav. 2013, 114-115:38-41.
12. Ebdrup B.H., Knop F.K., Ishoy P.L., Rostrup E., Fagerlund B., Lublin H., Glenthoj B. Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. BMC Med. 2012, 10:92.
13. Erreger K., Davis A.R., Poe A.M., Greig N.H., Stanwood G.D., Galli A. Exendin-4 decreases amphetamine-induced locomotor activity. Physiol. Behav. 2012, 106:574-578.
14. Ghosal S., Myers B., Herman J.P. Role of central glucagon-like peptide-1 in stress regulation. Physiol. Behav. 2013, 122:201-207.
15. Goodyer I.M., Bacon A., Ban M., Croudace T., Herbert J. Serotonin transporter genotype, morning cortisol and subsequent depression in adolescents. Br. J. Psychiatry 2009, 195:39-45.
16. Graham D.L., Erreger K., Galli A., Stanwood G.D. GLP-1 analog attenuates cocaine reward. Mol. Psychiatry 2013, 18:961-962.
17. Hayes M.R. Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects. Physiol. Behav. 2012, 106:413-416.
18. Hermes E., Nasrallah H., Davis V., Meyer J., McEvoy J., Goff D., Davis S., Stroup T.S., Swartz M., Lieberman J., Rosenheck R. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr. Res. 2011, 128:166-170.
19. Holscher C. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases. Biochem. Soc. Trans. 2014, 42:593-599.
20. Ishoy P.L., Knop F.K., Vilsboll T., Glenthoj B.Y., Ebdrup B.H. Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. Am. J. Psychiatry 2013, 170:681-682.
21. Koole C., Wootten D., Simms J., Valant C., Miller L.J., Christopoulos A., Sexton P.M. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. Mol. Pharmacol. 2011, 80:486-497.
22. Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009, 14:429-447.
23. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
24. Liu Q., Jamba M., Patrick C., Padmanabhan S., Brennan M.D. Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study. Pharmacogenomics 2012, 13:1227-1237.
25. Liu Q., Ramsey T.L., Meltzer H.Y., Massey B.W., Padmanabhan S., Brennan M.D. Sulfotransferase 4A1 haplotype 1 (SULT4A1-1) is associated with decreased hospitalization events in antipsychotic-treated patients with schizophrenia. Prim. Care Companion CNS Disord. 2012, 14.
26. Lykkegaard K., Larsen P.J., Vrang N., Bock C., Bock T., Knudsen L.B. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr. Res. 2008, 103:94-103.
27. McClay J.L., Adkins D.E., Aberg K., Bukszar J., Khachane A.N., Keefe R.S., Perkins D.O., McEvoy J.P., Stroup T.S., Vann R.E., Beardsley P.M., Lieberman J.A., Sullivan P.F., van den Oord E.J. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology 2011, 36:616-626.
28. McClay J.L., Adkins D.E., Aberg K., Stroup S., Perkins D.O., Vladimirov V.I., Lieberman J.A., Sullivan P.F., van den Oord E.J. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol. Psychiatry 2011, 16:76-85.
29. Need A.C., Keefe R.S., Ge D., Grossman I., Dickson S., McEvoy J.P., Goldstein D.B. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur. J. Hum. Genet. 2009, 17:946-957.
30. Ramsey T.L., Liu Q., Massey B.W., Brennan M.D. Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study. Schizophr. Res. 2013, 149:21-25.
31. Rupprecht L.E., Mietlicki-Baase E.G., Zimmer D.J., McGrath L.E., Olivos D.R., Hayes M.R. Hindbrain GLP-1 receptor-mediated suppression of food intake requires a PI3K-dependent decrease in phosphorylation of membrane-bound Akt. Am. J. Physiol. Endocrinol. Metab. 2013, 305:E751-E759.
32. Sathananthan A., Man C.D., Micheletto F., Zinsmeister A.R., Camilleri M., Giesler P.D., Laugen J.M., Toffolo G., Rizza R.A., Cobelli C., Vella A. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care 2010, 33:2074-2076.
33. Shah M., Vella A. Effects of GLP-1 on appetite and weight. Rev. Endocr. Metab. Disord. 2014, 15:181-187.
34. Sharma A.N., Ligade S.S., Sharma J.N., Shukla P., Elased K.M., Lucot J.B. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metab. Brain Dis. 2014, 2014 Jul 15 [Epub ahead of print]. See http://www.ncbi.nlm.nih.gov/pubmed/25023888.
35. Sharma A.N., Pise A., Sharma J.N., Shukla P. Dipeptidyl-peptidase IV (DPP-IV) inhibitor delays tolerance to anxiolytic effect of ethanol and withdrawal-induced anxiety in rats. Metab. Brain Dis. 2014, 2014 Aug 17 [Epub ahead of print]. See http://www.ncbi.nlm.nih.gov/pubmed/25129124.
36. Sheikh H.I., Dougherty L.R., Hayden E.P., Klein D.N., Singh S.M. Glucagon-like peptide-1 receptor gene polymorphism (Leu260Phe) is associated with morning cortisol in preschoolers. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:980-983.
37. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., McGee M.F., Simpson G.M., Stevens M.C., Lieberman J.A. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003, 29:15-31.
38. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Capuano G.A., Rosenheck R.A., Keefe R.S., Miller A.L., Belz I., Hsiao J.K. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am. J. Psychiatry 2007, 164:415-427.
39. van den Oord E.J., Adkins D.E., McClay J., Lieberman J., Sullivan P.F. A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr. Res. 2009, 107:13-21.